A two-stage prediction model for heterogeneous effects of many treatment options: application to drugs for Multiple Sclerosis

by   Konstantina Chalkou, et al.

Treatment effects vary across different patients and estimation of this variability is important for clinical decisions. The aim is to develop a model to estimate the benefit of alternative treatment options for individual patients. Hence, we developed a two-stage prediction model for heterogeneous treatment effects, by combining prognosis research and network meta-analysis methods when individual patient data is available. In a first stage, we develop a prognostic model and we predict the baseline risk of the outcome. In the second stage, we use this baseline risk score from the first stage as a single prognostic factor and effect modifier in a network meta-regression model. We apply the approach to a network meta-analysis of three randomized clinical trials comparing the relapse rate in Natalizumab, Glatiramer Acetate and Dimethyl Fumarate including 3590 patients diagnosed with relapsing-remitting multiple sclerosis. We find that the baseline risk score modifies the relative and absolute treatment effects. Several patient characteristics such as age and disability status impact on the baseline risk of relapse, and this in turn moderates the benefit that may be expected for each of the treatments. For high-risk patients, the treatment that minimizes the risk to relapse in two years is Natalizumab, whereas for low-risk patients Dimethyl Fumarate Fumarate might be a better option. Our approach can be easily extended to all outcomes of interest and has the potential to inform a personalised treatment approach.


Combining randomized and non-randomized data to predict heterogeneous effects of competing treatments

Some patients benefit from a treatment while others may do so less or do...

Personalized Prediction of Future Lesion Activity and Treatment Effect in Multiple Sclerosis from Baseline MRI

Precision medicine for chronic diseases such as multiple sclerosis (MS) ...

Decision curve analysis for personalized treatment choice between multiple options

Decision curve analysis can be used to determine whether a personalized ...

Augmented Learning of Heterogeneous Treatment Effects via Gradient Boosting Trees

Heterogeneous treatment effects (HTE) based on patients' genetic or clin...

An explainable model to support the decision about the therapy protocol for AML

Acute Myeloid Leukemia (AML) is one of the most aggressive types of hema...

Development, validation and clinical usefulness of a prognostic model for relapse in relapsing-remitting multiple sclerosis

Prognosis on the occurrence of relapses in individuals with Relapsing-Re...

Methodological concerns about 'concordance-statistic for benefit' as a measure of discrimination in treatment benefit prediction

Prediction algorithms that quantify the expected benefit of a given trea...

Please sign up or login with your details

Forgot password? Click here to reset